In 2010, CRI researchers Drew Pardoll, M.D., Ph.D., Susan Topalian, M.D., and
colleagues completed a phase I study showing that a PD -1-specific monoclonal antibody induces frequent tumor regressions in patients with advanced melanoma, renal cancer, lung cancer, and colon cancer with very low rates of toxicity.
After
completing these two courses and «meeting» her shelter medicine
colleagues she is more confident that this is the right direction for her to follow in the second
phase of her veterinary career.